Actor Pharmaceuticals and Megalabs Partner for FYB203 Commercialization

Formycon AG has announced partnerships with Actor Pharmaceuticals and Megalabs for the commercialization of its Eylea® biosimilar FYB203 in Australia and Latin America. The agreements, managed by Klinge Biopharma GmbH, involve upfront and milestone payments, alongside royalties on sales. Formycon will support the supply chain for FYB203 and receive additional service payments.

The aflibercept-based biosimilar FYB203 has received approvals from the FDA, European Commission, and MHRA. In Australia, the product awaits regulatory approval from the Therapeutic Goods Administration. Authorizations in Latin America are in progress with Megalabs.

Eylea® treats severe retinal diseases, including neovascular age-related macular degeneration, by inhibiting VEGF-induced blood vessel formation.